Sanofi said on 12 August it has stopped supplying its cholesterol-lowering drug Praluent to mainland China, citing a surge in demand that has outstripped current production capacity. The French group, which co-developed the treatment with Regeneron Pharmaceuticals, did not specify when deliveries would resume. The company told Reuters it is expanding global manufacturing for Praluent but, in the interim, is working with Chinese healthcare providers to move patients to other medicines already listed on the country’s National Reimbursement Drug List. Sanofi added that shortages have also been reported in several other markets. The move makes Sanofi the latest multinational to pull a popular medicine from the Chinese market because of supply constraints, following Merck’s suspension of Gardasil HPV-vaccine shipments earlier this year. Sanofi said it remains committed to meeting rising global demand once additional capacity comes online.